Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Cash from Investing Activities (2019 - 2025)

Summit Therapeutics (SMMT) has disclosed Cash from Investing Activities for 7 consecutive years, with -$485.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Investing Activities fell 681.15% year-over-year to -$485.2 million, compared with a TTM value of -$174.3 million through Dec 2025, up 15.11%, and an annual FY2025 reading of -$174.3 million, up 15.11% over the prior year.
  • Cash from Investing Activities was -$485.2 million for Q4 2025 at Summit Therapeutics, down from -$71000.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $160.1 million in Q1 2025 and bottomed at -$645.1 million in Q1 2023.
  • Average Cash from Investing Activities over 5 years is -$48.4 million, with a median of -$55000.0 recorded in 2021.
  • Peak annual rise in Cash from Investing Activities hit 605580.0% in 2023, while the deepest fall reached 178587.81% in 2023.
  • Year by year, Cash from Investing Activities stood at -$120000.0 in 2021, then soared by 108.33% to $10000.0 in 2022, then soared by 605580.0% to $60.6 million in 2023, then surged by 37.83% to $83.5 million in 2024, then crashed by 681.15% to -$485.2 million in 2025.
  • Business Quant data shows Cash from Investing Activities for SMMT at -$485.2 million in Q4 2025, -$71000.0 in Q3 2025, and $150.8 million in Q2 2025.